Dow Surges 300 Points; Johnson & Johnson Posts Upbeat Earnings
Portfolio Pulse from Lisa Levin
The Dow Jones Industrial Average rose by 0.87% while the NASDAQ and S&P 500 fell by 1.11% and 0.19% respectively. Johnson & Johnson (JNJ) reported better-than-expected Q2 earnings and sales, and raised its FY23 guidance. T2 Biosystems (TTOO), Pasithea Therapeutics (KTTA), and SigmaTron International (SGMA) saw their shares rise, while Vir Biotechnology (VIR), Netcapital (NCPL), and Aspira Women's Health (AWH) saw their shares fall.
July 20, 2023 | 4:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson reported better-than-expected Q2 earnings and sales, and raised its FY23 guidance.
Johnson & Johnson's better-than-expected earnings and sales results, along with raised guidance for FY23, are likely to have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Pasithea Therapeutics shares rose after the company rejected an acquisition proposal and authorized a share repurchase.
Pasithea Therapeutics' rejection of an acquisition proposal and authorization of a share repurchase are likely to have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
SigmaTron International shares rose after the company reported Q4 results.
SigmaTron International's Q4 results are likely to have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
T2 Biosystems shares rose after the FDA granted Breakthrough Device designation for the company's Candida auris direct-from-blood molecular diagnostic test.
The FDA's Breakthrough Device designation for T2 Biosystems' diagnostic test is likely to have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Aspira Women's Health shares fell after the company announced a registered direct offering.
Aspira Women's Health's announcement of a registered direct offering is likely to have a negative impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Netcapital shares fell after the company announced the pricing of a public offering.
Netcapital's announcement of the pricing of a public offering is likely to have a negative impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Vir Biotechnology shares fell after the company's Phase 2 trial did not meet primary or secondary efficacy endpoints.
The failure of Vir Biotechnology's Phase 2 trial to meet primary or secondary efficacy endpoints is likely to have a negative impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100